These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 36433637)
1. Li X; Chen Z; Jiao J; Wang S; Wang Y; Wu W; Yang H; Lou H Expert Rev Anti Infect Ther; 2023 Jan; 21(1):91-98. PubMed ID: 36433637 [TBL] [Abstract][Full Text] [Related]
2. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934 [TBL] [Abstract][Full Text] [Related]
3. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex. Li W; Zhang J; Fu Y; Wang J; Liu L; Long W; Yu K; Li X; Wei C; Liang X; Wang J; Li C; Zhang X Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1309-1318. PubMed ID: 38700663 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates. Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae. Huang YS; Yang JL; Wang JT; Sheng WH; Yang CJ; Chuang YC; Chang SC J Infect Public Health; 2024 May; 17(5):929-937. PubMed ID: 38599013 [TBL] [Abstract][Full Text] [Related]
7. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens]. Köle M; Sesli Çetin E; Şirin MC; Cicioğlu Arıdoğan B Mikrobiyol Bul; 2022 Apr; 56(2):230-250. PubMed ID: 35477227 [TBL] [Abstract][Full Text] [Related]
9. Captopril potentiated meropenem activity against MBL-producing carbapenem-resistant Klebsiella pneumoniae: in vitro and in vivo study. Zhao D; Li H; Yue C; Sun K; Dai Y; Zhang H; Liu Y; Gao Y; Li J J Inorg Biochem; 2021 May; 218():111381. PubMed ID: 33647540 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755 [TBL] [Abstract][Full Text] [Related]
12. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067 [TBL] [Abstract][Full Text] [Related]
13. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421 [TBL] [Abstract][Full Text] [Related]
14. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541 [TBL] [Abstract][Full Text] [Related]
15. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates. Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356 [TBL] [Abstract][Full Text] [Related]
16. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106 [TBL] [Abstract][Full Text] [Related]
17. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Lee YL; Ko WC; Hsueh PR Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011 [TBL] [Abstract][Full Text] [Related]
18. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044 [TBL] [Abstract][Full Text] [Related]